Methylprednisolone
Summary of product characteristics
Effective Time
20221031
Version
5
Spl Product Data Elements
methylprednisolone methylprednisolone METHYLPREDNISOLONE METHYLPREDNISOLONE CELLULOSE, MICROCRYSTALLINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO STARCH, CORN WHITE TO OFF-WHITE OVAL 916 methylprednisolone methylprednisolone METHYLPREDNISOLONE METHYLPREDNISOLONE CELLULOSE, MICROCRYSTALLINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO STARCH, CORN WHITE TO OFF-WHITE OVAL 917 methylprednisolone methylprednisolone METHYLPREDNISOLONE METHYLPREDNISOLONE CELLULOSE, MICROCRYSTALLINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO STARCH, CORN WHITE TO OFF-WHITE OVAL 918 methylprednisolone methylprednisolone METHYLPREDNISOLONE METHYLPREDNISOLONE CELLULOSE, MICROCRYSTALLINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO STARCH, CORN WHITE TO OFF-WHITE OVAL 919
Application Number
ANDA206751
Brand Name
Methylprednisolone
Generic Name
methylprednisolone
Product Ndc
70771-1350
Product Type
HUMAN PRESCRIPTION DRUG
Route
ORAL
Package Label Principal Display Panel
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1348-1 in bottle of 100 tablets Methylprednisolone tablets, USP R x only 100 tablets NDC 70771-1349-8 in bottle of 25 tablets Methylprednisolone tablets, USP R x only 25 tablets NDC 70771-1350-7 in bottle of 50 tablets Methylprednisolone tablets, USP R x only 50 tablets NDC 70771-1351-8 in bottle of 25 tablets Methylprednisolone tablets, USP R x only 25 tablets methylprednisolone tablets methylprednisolone tablets methylprednisolone tablets methylprednisolone tablets
1 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
Disclaimer
The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).
Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.